FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
An abstract is unavailable.
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products